Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5092351 | 0.94 | KMT2A (0.65) | KMT2AMEN1CD274SMN1; SMN2KDM4E | |
| SCHEMBL5092228 | 0.90 | MEN1 (0.71) | KMT2AMEN1CD274SMN1; SMN2 | |
| SCHEMBL5105512 | 0.87 | MEN1 (0.77) | KMT2AMEN1CD274SMN1; SMN2 | |
| SCHEMBL5092330 | 0.84 | MEN1 (0.73) | KMT2AMEN1CD274SMN1; SMN2KDM4E | |
| SCHEMBL5099016 | 0.83 | MEN1 (0.62) | KMT2AMEN1CD274 | |
| SCHEMBL5092343 | 0.81 | KMT2A (0.67) | KMT2AMEN1CD274SMN1; SMN2KDM4E | |
| SCHEMBL5105109 | 0.81 | MEN1 (0.67) | KMT2AMEN1CD274 | |
| SCHEMBL3039929 | 0.80 | KMT2A (0.66) | KMT2AMEN1CD274SMN1; SMN2RAB9A | |
| SCHEMBL5098986 | 0.80 | CD274 (0.66) | KMT2AMEN1CD274SMN1; SMN2RAB9A | |
| SCHEMBL5096313 | 0.80 | KMT2A (0.66) | KMT2AMEN1CD274SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | claimed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | claimed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | claimed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | claimed |
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | disclosed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | SCN7A, HTR7, TRPC7 | KMT2A 4198/4885MEN1 718/4885CD274 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.